Novartis' Myfortic Placed On China's National Drug Reimbursement List, Strengthens Portfolio On Immunosuppressant Therapy
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novartis immunosuppressant therapy Myfortic (mycophenolate sodium) was recently added to China's revised National Drug Reimbursement List